EU Health Product Manufacturers Call for Guidance on Flexibility of Claims Wording

09 Feb 2012 --- Welcoming the European Commission’s decision to allow the food sector some flexibility when making claims, EHPM said that because of concerns that the average consumer will not understand some of the scientific terminology, claims should be accompanied by further explanatory details.

Feb 9 2012 --- Guidance on the acceptability of flexible wordings when communicating article 13.1 health claims to consumers will be valuable for both enforcement bodies and companies, the European Federation of Associations of Health Product Manufacturers (EHPM) has said.

Welcoming the European Commission’s decision to allow the food sector some flexibility when making claims, EHPM said that because of concerns that the average consumer will not understand some of the scientific terminology, claims should be accompanied by further explanatory details.

“We have concerns whether the average consumer will understand scientific terminology such as ‘Homocystein metabolism’, ‘normal neurotransmission’, ‘cell division and differentiation’ and ‘sulphur amino acid metabolism’,” said EHPM Chairman Peter van Doorn. “Consumers may not interpret correctly many of the wordings listed in the annex of the draft Regulation establishing a list of permitted health claims. Therefore, it is essential that wordings can be adapted to consumer language.”

The European trade association highlighted the dual and equal requirement in the Regulation for claims to be “based on generally accepted scientific evidence” and “well understood by the average consumer”.

EHPM said that based on these requirements companies should be permitted to mention some of the specific functions and definitions cited in the European Food Safety Authority’s (EFSA) opinions, stating that this would provide consumers with valuable advice.
 
“We believe that such clarifications would greatly assist consumer understanding,” said van Doorn. “For example, a message such as ‘Pantothenic acid contributes to normal mental performance’, which relates to EFSA’s definition of mental performance as standing for those aspects of brain and nerve functions which determine aspects like concentration, learning, memory and reasoning. We hope that the European Commission and Member States take into consideration this approach with regard to flexibility.”

Related Articles

Business News

Dynamic OTC marketplace: Albertsons and Rite Aid merge, Amazon enters the fray

21 Feb 2018 --- Albertsons Companies, one of the US’ largest grocery retailers, and leading drugstore chain Rite Aid Corporation have announced a definitive merger agreement, creating a retail behemoth with US$83 billion in annual revenue. The move is thought to give the integrated company more weight to compete with bigger chains in an industry anxious about the reported entry of Amazon.com.

Nutrition & Health News

“Unhelpful”: EU regulatory framework fuels nutrition industry dissatisfaction 

16 Feb 2018 --- A survey reveals that one-third of all nutrition industry professionals believe that the current EU framework for achieving a health claim on new products is stunting innovation because it’s complicated, expensive, long-winded and has several “gray areas.” And “regulation frustration” is a strong feeling running through the industry with many more professionals now believing the current EU regulatory environment is “unhelpful” – a 25 percent hike compared with statistics from the beginning of 2017. Experts are attributing this sharp rise in dissatisfaction to the EU’s tough stance on health claims and the current regulatory deadlock on botanicals.

Nutrition & Health News

Clear definition and regulations needed to tap into nutraceuticals’ potential: review

13 Feb 2018 --- Nutraceuticals with health benefits substantiated by clinical data can be powerful tools to prevent and treat medical conditions, especially in individuals who may not yet be eligible for conventional pharmaceutical drugs. However, there is a clear need for clear regulations to ensure their safety. This is according to a review published in the British Journal of Clinical Pharmacology, which further proposes a clear definition for this type of product. 

Nutrition & Health News

EID Parry and Synthite Industries partner on phycocyanin production 

08 Feb 2018 --- Enhanced health company Valensa International has entered into a joint venture agreement between Valensa’s parent company EID Parry and Synthite Industries Ltd, which promises to boost microalgae extracts for nutraceutical applications. It involves a US$6.5 million investment in an India-based manufacturing facility for the extraction of Parry Organic Spirulina to produce Phycocyanin, which Valensa will be developing for dietary supplements, functional and medical foods.

Nutrition & Health News

Immunity boosters (Part 1): Not diplomatic about immunity – Trends, opportunities and delivery systems

06 Feb 2018 --- Immunity boosters are a popular way of staying on top of immune health: from capsules and tablets to fortified food and beverages, these ingredients are in demand all year round thanks to their protective qualities. Today, NutritionInsight takes a look at the latest developments on the immunity platform.

More Articles
URL : http://www.nutritioninsight.com:80/news/EU-Health-Product-Manufacturers-Call-for-Guidance-on-Flexibility-of-Claims-Wording.html